Formulation of nanoparticles loaded in situ gel for treatment of dry eye disease: In vitro, ex vivo and in vivo evidences

Author(s):  
Umesh D. Laddha ◽  
Sanjay J. Kshirsagar
Pharmaceutics ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 1698
Author(s):  
Ana López-Machado ◽  
Natalia Díaz-Garrido ◽  
Amanda Cano ◽  
Marta Espina ◽  
Josefa Badia ◽  
...  

Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED.


2019 ◽  
Vol 17 (2) ◽  
pp. 257-264 ◽  
Author(s):  
Agnė Žiniauskaitė ◽  
Symantas Ragauskas ◽  
Anita K. Ghosh ◽  
Rubina Thapa ◽  
Anne E. Roessler ◽  
...  

2021 ◽  
Vol 22 (3) ◽  
Author(s):  
Soad A. Mohamad ◽  
Eman Alaaeldin ◽  
Raafat M. A. Abdallah ◽  
Heba F. Mansour

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Bongkyun Park ◽  
Tae Gu Lee ◽  
Soo‐Wang Hyun ◽  
Kyuhyung Jo ◽  
Ik Soo Lee ◽  
...  
Keyword(s):  
Dry Eye ◽  

2021 ◽  
Vol 22 (3) ◽  
Author(s):  
Soad A. Mohamad ◽  
Eman Alaaeldin ◽  
Raafat M. A. Abdallah ◽  
Heba F. Mansour

2021 ◽  
Vol Volume 15 ◽  
pp. 2357-2373
Author(s):  
Baorui Ma ◽  
Linnuo Pang ◽  
Pingqing Huang ◽  
Jie Bai ◽  
Zhiqin Zhang ◽  
...  

2021 ◽  
Vol 22 (22) ◽  
pp. 12102
Author(s):  
Md. Mahbubur Rahman ◽  
Dong Hyun Kim ◽  
Chul-Kyu Park ◽  
Yong Ho Kim

Dry eye disease (DED) is one of the major ophthalmological healthcare challenges worldwide. DED is a multifactorial disease characterized by a loss of homeostasis of the tear film, and its main pathogenesis is chronic ocular surface inflammation related with various cellular and molecular signaling cascades. The animal model is a reliable and effective tool for understanding the various pathological mechanisms and molecular cascades in DED. Considerable experimental research has focused on developing new strategies for the prevention and treatment of DED. Several experimental models of DED have been developed, and different animal species such as rats, mice, rabbits, dogs, and primates have been used for these models. Although the basic mechanisms of DED in animals are nearly identical to those in humans, proper knowledge about the induction of animal models is necessary to obtain better and more reliable results. Various experimental models (in vitro and in vivo DED models) were briefly discussed in this review, along with pathologic features, analytical approaches, and common measurements, which will help investigators to use the appropriate cell lines, animal, methods, and evaluation parameters depending on their study design.


2019 ◽  
Vol 11 ◽  
pp. 251584141987036 ◽  
Author(s):  
Stacy L. Haber ◽  
Vera Benson ◽  
Casey J. Buckway ◽  
Jennifer M. Gonzales ◽  
David Romanet ◽  
...  

The objective of this article is to review the pharmacology, efficacy, and safety of lifitegrast and determine its role relative to other agents in the management of dry eye disease. A PubMed search (1946 to December 2018) using the terms lifitegrast and SAR 1118 was conducted to identify relevant articles. In vitro or in vivo evaluations of lifitegrast published in the English language were eligible for inclusion. Phase II and III trials were selected for review of efficacy and safety. Four randomized controlled trials evaluated the efficacy and safety of lifitegrast 0.5% ophthalmic solution for 12 weeks, and 1 additional trial assessed safety for 1 year. In a majority of the trials, lifitegrast caused statistically significant improvements in inferior corneal fluorescein staining scores and eye dryness scores. The most common adverse effects were eye irritation, dysgeusia, and reduced visual acuity, and most were mild to moderate in severity. Lifitegrast has a novel mechanism of action and is safe and effective for the treatment of dry eye disease. At this time, lifitegrast may be considered as an option for patients who have an inadequate response to artificial tears.


2019 ◽  
Vol 554 ◽  
pp. 264-275 ◽  
Author(s):  
Ketan M. Ranch ◽  
Furqan A. Maulvi ◽  
Mausam J. Naik ◽  
Akshay R. Koli ◽  
Rajesh K. Parikh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document